Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

0.7836 +0.0069 (+0.89%)
Streaming Delayed Price Updated: 2:41 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Is COVID-19 Antibody Focused Invivyd Stock Trading Over 150% Higher Today?
Invivyd Inc (NASDAQ: IVVD) shares are trading higher after the company released initial results from the ongoing CANOPY Phase 3 pivotal clinical trial of VYD222, a broadly neutralizing, half-life... 
Via Benzinga
Exposures COVID-19
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
From Invivyd
Via GlobeNewswire
Recap: Invivyd Q3 Earnings
Via Benzinga
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd's Earnings: A Preview
Via Benzinga
What 4 Analyst Ratings Have To Say About Invivyd
Via Benzinga
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
Initial primary endpoint data anticipated in late 2023 or early Q1 2024 
From Invivyd
Via GlobeNewswire
7 Biotech Stocks to Sell in September Before They Crash & Burn
These are just a few of the top biotech stocks to sell today - especially with each of the firms dealing with legitimate issues. 
Via InvestorPlace
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
Invivyd Appoints William Duke as Chief Financial Officer
From Invivyd
Via GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Dentsply, and Invivyd on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
From Invivyd
Via GlobeNewswire
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People
Invivyd Inc (NASDAQ: IVVD) announced additional initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal  
Via Benzinga
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
From Kahn Swick & Foti, LLC
Via Business Wire
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
From Invivyd
Via GlobeNewswire
Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19
Invivyd Inc (NASDAQ: IVVD) announces initial data from its ongoing Phase 1 healthy volunteer clinical trial of VYD222, its investigational monoclonal  
Via Benzinga
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
From Invivyd
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Invivyd to Participate at the Jefferies Healthcare Conference
From Invivyd
Via GlobeNewswire
INVIVYD ALERT: Bragar Eagel & Squire, P.C. is Investigating Invivyd, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NASDAQ:IVVD Long Term Investor Alert: Investigation over Potential Wrongdoing at Invivyd, Inc.
San Diego, CA -- (SBWIRE) -- 05/25/2023 -- An investigation was announced on behalf of investors in shares of Invivyd, Inc. (NASDAQ:IVVD) over possible breaches of fiduciary duties by certain directors... 
Via SBWire
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS